MIPI Score
Enter patient age, ECOG performance status, LDH (and lab upper limit), and white blood cell count to calculate the Mantle Cell International Prognostic Index.
MIPI score
3.83
Risk group
Low risk
5-year overall survival: 83%
How to Use This Calculator
Collect baseline mantle cell lymphoma data
Confirm LDH level and lab upper limit, WBC count, age, and ECOG performance status at diagnosis.
Enter values accurately
Use LDH ratio (LDH ÷ ULN) and WBC in ×10⁹/L. Performance status 0–1 counts as 0, 2–4 counts as 1 in the formula.
Apply risk stratification to guide management
Use risk category alongside Ki-67, cytogenetics, and patient fitness to select frontline therapy and clinical trial options.
Formula
MIPI = 0.03535 × Age + 0.6978 × PS + 1.367 × log10(LDH ÷ ULN) + 0.9393 × log10(WBC)
PS = 0 if ECOG 0–1, 1 if ECOG 2–4.
Risk groups: <5.7 (low), 5.7–<6.2 (intermediate), ≥6.2 (high).
Full Description
The Mantle Cell International Prognostic Index (MIPI) quantifies prognosis in mantle cell lymphoma using age, performance status, LDH ratio, and leukocyte count. Developed in the rituximab era, it correlates with overall survival and helps tailor therapy intensity. Incorporate proliferation markers (Ki-67), cytogenetic abnormalities, and novel biomarkers when refining risk and treatment plans.
Frequently Asked Questions
Can MIPI be used after treatment?
MIPI is validated at diagnosis. Post-treatment assessments should consider response criteria, MRD status, and relapse biology.
How does Ki-67 affect risk?
High Ki-67 (>30%) indicates aggressive disease. Combine with MIPI to form the MIPI-c (combined) for enhanced prognostication.
What if LDH is normal?
LDH ratio will be ≤1.0, reducing the score. Persisting low-risk features suggest better prognosis.
Does WBC include lymphocyte count only?
Use total leukocyte count (×10⁹/L) from the complete blood count as specified in the original MIPI study.